.svg.png){kind=small}
.svg){kind=small}
They have three programs, two of these programs are in clinical development and one is at an early stage of development, each is intended to treat rare and progressive kidney disease modulated by aberrant purine and uric acid metabolism.
XORTX Therapeutics, Inc. is a drug-based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Their focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.
They possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.
For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.
.png){kind=small}
